Table 1.
Therapeutic agents currently under investigation in clinical trials for the treatment of chronic spontaneous urticaria, May 2022.
| Molecule | Mechanism | Type | Stage | Indication |
|---|---|---|---|---|
| CDX-0159 | Anti-tyrosine kinase KIT | mAb | 1 | CSU and chronic inducible urticaria [63] |
| Mepolizumab | Anti-IL-5 | mAb | 1 | CSU [64] |
| Ligelizumab | Anti-IgE | mAb | 2 | CSU in children from 12 to <18 years of age [65] |
| Dupilumab | Anti-IL-4/-13 | mAb | 2 | CSU [66] |
| MTPS9579A | Tetrameric β-tryptase | mAb | 2 | CSU [59] |
| Tezepelumab | Thymic stromal lymphopoietin | mAb | 2 | CSU [67] |
| Remibrutinib | Anti-BTK | Small molecule | 3 | CSU [68] |
| Benralizumab | Anti-IL-5 receptor | mAb | 4 | CSU [69] |
Abbreviations: KIT: Tyrosine kinase; IgE: Immunoglobulin E; IL: Interleukin; BTK: Bruton tyrosine kinase; CSU: Chronic spontaneous urticaria; mAB: Monoclonal antibody.